<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2195">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595516</url>
  </required_header>
  <id_info>
    <org_study_id>BYS-MD-72</org_study_id>
    <nct_id>NCT01595516</nct_id>
  </id_info>
  <brief_title>Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)</brief_title>
  <official_title>Nebivolol and Endothelial Regulation of Fibrinolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Boulder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Boulder</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult&#xD;
      humans with elevated blood pressure to a greater extent than either metoprolol or placebo.&#xD;
      The investigators further hypothesize that the improvement in the capacity of the vascular&#xD;
      endothelium to release t-PA with nebivolol is mediated, in part, by the compound's&#xD;
      antioxidant properties.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Heart rate was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
    <description>Resting heart rate in the seated position</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Systolic blood pressure was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Diastolic blood pressure was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial t-PA Release in Response to Bradykinin (BDK) Before and After the 12 Week Intervention</measure>
    <time_frame>t-PA release was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
    <description>Net endothelial release of t-PA antigen in response to bradykinin (BDK) was calculated using the following equation: Net Release of t-PA Antigen=(Cv-Ca) x (FBF x [101-hematocrit/100]) where Cv and Ca represent the concentration of t-PA in the vein and artery respectively. A positive difference indicates a net release and a negative difference net uptake. Arterial and venous blood samples are collected simultaneously at baseline and each dose of the drug (BDK). t-PA concentration were determined by enzyme immunoassay. Hematocrit was measured in triplicate using the standard microhematocrit technique and corrected for trapped plasma volume within the trapped red blood cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial t-PA Release in Response to Bradykinin (BDK) and Bradykinin+Vitamin C (BDK+C) Before and After 12 Weeks of Nebivolol Therapy.</measure>
    <time_frame>t-PA release was measured before the 12 week drug intervention and after the 12 week drug intervention.</time_frame>
    <description>Net endothelial release of t-PA antigen in response to bradykinin (BDK) and bradykinin+vitamin C (BDK+C) was calculated using the following equation: Net Release of t-PA Antigen=(Cv-Ca) x (FBF x [101-hematocrit/100]) where Cv and Ca represent the concentration of t-PA in the vein and artery respectively. A positive difference indicates a net release and a negative difference net uptake. Arterial and venous blood samples are collected simultaneously at baseline and each dose of the drug (BDK) and BDK+Vit C. t-PA concentration were determined by enzyme immunoassay. Hematocrit was measured in triplicate using the standard microhematocrit technique and corrected for trapped plasma volume within the trapped red blood cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial t-PA Release in Response to BDK and BDK+C Before and After 12 Weeks of Metoprolol Therapy.</measure>
    <time_frame>t-PA release was measured before the 12 week drug intervention and after the 12 week drug intervention.</time_frame>
    <description>Net endothelial release of t-PA antigen in response to BDK and BDK+C was calculated using the following equation: Net Release of t-PA Antigen=(Cv-Ca) x (FBF x [101-hematocrit/100]) where Cv and Ca represent the concentration of t-PA in the vein and artery respectively. A positive difference indicates a net release and a negative difference net uptake. Arterial and venous blood samples are collected simultaneously at baseline and each dose of the drug (BDK) and BDK+Vit C. t-PA concentration were determined by enzyme immunoassay. Hematocrit was measured in triplicate using the standard microhematocrit technique and corrected for trapped plasma volume within the trapped red blood cells.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Prehypertension</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bradykinin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>5 mg tablet to be taken by mouth once per day for 12 weeks</description>
    <arm_group_label>Bradykinin</arm_group_label>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_label>Vitamin C</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>100 mg tablet to be taken by mouth once per day for 12 weeks</description>
    <arm_group_label>Bradykinin</arm_group_label>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_label>Vitamin C</arm_group_label>
    <other_name>Toprol-XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gelatin capsule to be taken by mouth once per day for 12 weeks</description>
    <arm_group_label>Bradykinin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bradykinin</intervention_name>
    <description>Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.</description>
    <arm_group_label>Bradykinin</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_label>Vitamin C</arm_group_label>
    <other_name>BDK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.</description>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.</description>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years.&#xD;
&#xD;
          -  Subjects will be prehypertensive/hypertensive defined as resting systolic blood&#xD;
             pressure &gt;125 mmHg and &lt;160 mmHg and/or diastolic &gt;80 mmHg and &lt;100 mmHg.&#xD;
&#xD;
          -  All of the women in the study will be postmenopausal and not receiving hormone&#xD;
             replacement therapy (HRT) currently or in the preceding 3-year period.&#xD;
&#xD;
          -  Candidates will be sedentary as determined from the Stanford Physical Activity&#xD;
             Questionnaire (&lt;35 kcal/wk) and will not have engaged in any program of regular&#xD;
             physical activity for at least 1 year prior to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Candidates who smoke (currently or in the past 7 years), report more than low-risk&#xD;
             alcohol consumption as defined as no more than 14 standard drinks/wk and no more than&#xD;
             4 standard drinks/day for men and 7 standard drinks/wk and 3 standard drinks/day for&#xD;
             women (a standard drink is defined as 12 ounces of beer, 5 ounces of wine, 1½ ounces&#xD;
             of 80-proof distilled spirits).&#xD;
&#xD;
          -  Potential candidates who are taking cardiovascular-acting (i.e. statins, blood&#xD;
             pressure medication and aspirin) medications will not be eligible.&#xD;
&#xD;
          -  Fasting plasma glucose &gt;126 mg/dL.&#xD;
&#xD;
          -  Potential candidates with a resting heart rate of &lt; 50 beats/minute will be excluded.&#xD;
&#xD;
          -  Use of hormone replacement therapy.&#xD;
&#xD;
          -  In hypertensive subjects, a seated systolic blood pressure &gt;160 mmHg or a seated&#xD;
             diastolic blood pressure &gt;100 mmHg will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher DeSouza, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado at Boulder</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC-Boulder Clinical and Translational Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <results_first_submitted>May 1, 2019</results_first_submitted>
  <results_first_submitted_qc>June 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2019</results_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado, Boulder</investigator_affiliation>
    <investigator_full_name>Christopher DeSouza</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
    <mesh_term>Bradykinin</mesh_term>
    <mesh_term>Kininogens</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 25, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT01595516/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nebivolol</title>
          <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Metoprolol</title>
          <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo: Gelatin capsule to be taken by mouth once per day for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nebivolol</title>
          <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Metoprolol</title>
          <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: Gelatin capsule to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="5"/>
                    <measurement group_id="B2" value="58" spread="6"/>
                    <measurement group_id="B3" value="57" spread="6"/>
                    <measurement group_id="B4" value="58" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate</title>
        <description>Resting heart rate in the seated position</description>
        <time_frame>Heart rate was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Gelatin capsule to be taken by mouth once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>Resting heart rate in the seated position</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" spread="1"/>
                    <measurement group_id="O2" value="71" spread="1"/>
                    <measurement group_id="O3" value="69" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="2"/>
                    <measurement group_id="O2" value="64" spread="3"/>
                    <measurement group_id="O3" value="72" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure</title>
        <time_frame>Systolic blood pressure was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Gelatin capsule to be taken by mouth once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140" spread="2"/>
                    <measurement group_id="O2" value="138" spread="2"/>
                    <measurement group_id="O3" value="138" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" spread="2"/>
                    <measurement group_id="O2" value="125" spread="3"/>
                    <measurement group_id="O3" value="135" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diastolic Blood Pressure</title>
        <time_frame>Diastolic blood pressure was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Gelatin capsule to be taken by mouth once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="2"/>
                    <measurement group_id="O2" value="87" spread="2"/>
                    <measurement group_id="O3" value="85" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="2"/>
                    <measurement group_id="O2" value="79" spread="2"/>
                    <measurement group_id="O3" value="81" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endothelial t-PA Release in Response to Bradykinin (BDK) Before and After the 12 Week Intervention</title>
        <description>Net endothelial release of t-PA antigen in response to bradykinin (BDK) was calculated using the following equation: Net Release of t-PA Antigen=(Cv-Ca) x (FBF x [101-hematocrit/100]) where Cv and Ca represent the concentration of t-PA in the vein and artery respectively. A positive difference indicates a net release and a negative difference net uptake. Arterial and venous blood samples are collected simultaneously at baseline and each dose of the drug (BDK). t-PA concentration were determined by enzyme immunoassay. Hematocrit was measured in triplicate using the standard microhematocrit technique and corrected for trapped plasma volume within the trapped red blood cells.</description>
        <time_frame>t-PA release was measured before the 12 week drug or placebo intervention and after the 12 week drug or placebo intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Nebivolol</title>
            <description>Before randomization to nebivolol</description>
          </group>
          <group group_id="O2">
            <title>After Nebivolol</title>
            <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Before Metoprolol</title>
            <description>Before randomization to metoprolol</description>
          </group>
          <group group_id="O4">
            <title>After Metoprolol</title>
            <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Before Placebo</title>
            <description>Before randomization to placebo</description>
          </group>
          <group group_id="O6">
            <title>After Placebo</title>
            <description>Placebo: Gelatin capsule to be taken by mouth once per day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial t-PA Release in Response to Bradykinin (BDK) Before and After the 12 Week Intervention</title>
          <description>Net endothelial release of t-PA antigen in response to bradykinin (BDK) was calculated using the following equation: Net Release of t-PA Antigen=(Cv-Ca) x (FBF x [101-hematocrit/100]) where Cv and Ca represent the concentration of t-PA in the vein and artery respectively. A positive difference indicates a net release and a negative difference net uptake. Arterial and venous blood samples are collected simultaneously at baseline and each dose of the drug (BDK). t-PA concentration were determined by enzyme immunoassay. Hematocrit was measured in triplicate using the standard microhematocrit technique and corrected for trapped plasma volume within the trapped red blood cells.</description>
          <units>ng/100 mL tissue/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amount of t-PA release to Saline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.8"/>
                    <measurement group_id="O2" value="-1.8" spread="0.9"/>
                    <measurement group_id="O3" value="-1.2" spread="1.2"/>
                    <measurement group_id="O4" value="-1.9" spread="1.1"/>
                    <measurement group_id="O5" value="-0.2" spread="1.2"/>
                    <measurement group_id="O6" value="-0.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amount of t-PA release to BDK 12.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="2.9"/>
                    <measurement group_id="O2" value="25.2" spread="4.1"/>
                    <measurement group_id="O3" value="14.4" spread="3.3"/>
                    <measurement group_id="O4" value="16.6" spread="3.3"/>
                    <measurement group_id="O5" value="18.1" spread="3.1"/>
                    <measurement group_id="O6" value="17.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amount of t-PA release to BDK 25.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="3.9"/>
                    <measurement group_id="O2" value="46.4" spread="6.5"/>
                    <measurement group_id="O3" value="27.5" spread="3.3"/>
                    <measurement group_id="O4" value="31.2" spread="2.4"/>
                    <measurement group_id="O5" value="28.3" spread="3.8"/>
                    <measurement group_id="O6" value="32.7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amount of t-PA release to BDK 50.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2" spread="4.3"/>
                    <measurement group_id="O2" value="72.8" spread="5.7"/>
                    <measurement group_id="O3" value="48.2" spread="5.9"/>
                    <measurement group_id="O4" value="52.7" spread="4.6"/>
                    <measurement group_id="O5" value="51.1" spread="5.0"/>
                    <measurement group_id="O6" value="52.9" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endothelial t-PA Release in Response to Bradykinin (BDK) and Bradykinin+Vitamin C (BDK+C) Before and After 12 Weeks of Nebivolol Therapy.</title>
        <description>Net endothelial release of t-PA antigen in response to bradykinin (BDK) and bradykinin+vitamin C (BDK+C) was calculated using the following equation: Net Release of t-PA Antigen=(Cv-Ca) x (FBF x [101-hematocrit/100]) where Cv and Ca represent the concentration of t-PA in the vein and artery respectively. A positive difference indicates a net release and a negative difference net uptake. Arterial and venous blood samples are collected simultaneously at baseline and each dose of the drug (BDK) and BDK+Vit C. t-PA concentration were determined by enzyme immunoassay. Hematocrit was measured in triplicate using the standard microhematocrit technique and corrected for trapped plasma volume within the trapped red blood cells.</description>
        <time_frame>t-PA release was measured before the 12 week drug intervention and after the 12 week drug intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Nebivolol: Saline</title>
            <description>Net t-PA antigen release in response to BDK before 12 weeks of nebivolol therapy.</description>
          </group>
          <group group_id="O2">
            <title>Before Nebivolol: Vitamin C</title>
            <description>Net t-PA antigen release in response to BDK+C before 12 weeks of nebivolol therapy.</description>
          </group>
          <group group_id="O3">
            <title>After Nebivolol: Saline</title>
            <description>Net t-PA antigen release in response to BDK after 12 weeks of nebivolol therapy.</description>
          </group>
          <group group_id="O4">
            <title>After Nebivolol: Vitamin C</title>
            <description>Net t-PA antigen release in response to BDK+C after 12 weeks of nebivolol therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial t-PA Release in Response to Bradykinin (BDK) and Bradykinin+Vitamin C (BDK+C) Before and After 12 Weeks of Nebivolol Therapy.</title>
          <description>Net endothelial release of t-PA antigen in response to bradykinin (BDK) and bradykinin+vitamin C (BDK+C) was calculated using the following equation: Net Release of t-PA Antigen=(Cv-Ca) x (FBF x [101-hematocrit/100]) where Cv and Ca represent the concentration of t-PA in the vein and artery respectively. A positive difference indicates a net release and a negative difference net uptake. Arterial and venous blood samples are collected simultaneously at baseline and each dose of the drug (BDK) and BDK+Vit C. t-PA concentration were determined by enzyme immunoassay. Hematocrit was measured in triplicate using the standard microhematocrit technique and corrected for trapped plasma volume within the trapped red blood cells.</description>
          <units>ng/100 mL tissue/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amount of t-PA release to saline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.1"/>
                    <measurement group_id="O2" value="-1.4" spread="0.8"/>
                    <measurement group_id="O3" value="-1.5" spread="1.3"/>
                    <measurement group_id="O4" value="-3.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amount of t-PA release to BDK 12.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="3.2"/>
                    <measurement group_id="O2" value="31.3" spread="5.5"/>
                    <measurement group_id="O3" value="28.2" spread="6.2"/>
                    <measurement group_id="O4" value="38.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amount of t-PA release to BDK 25.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="5.0"/>
                    <measurement group_id="O2" value="52.7" spread="6.6"/>
                    <measurement group_id="O3" value="49.1" spread="9.1"/>
                    <measurement group_id="O4" value="54.2" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amount of t-PA release to BDK 50.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2" spread="5.0"/>
                    <measurement group_id="O2" value="80.5" spread="6.2"/>
                    <measurement group_id="O3" value="67.5" spread="7.1"/>
                    <measurement group_id="O4" value="79.9" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endothelial t-PA Release in Response to BDK and BDK+C Before and After 12 Weeks of Metoprolol Therapy.</title>
        <description>Net endothelial release of t-PA antigen in response to BDK and BDK+C was calculated using the following equation: Net Release of t-PA Antigen=(Cv-Ca) x (FBF x [101-hematocrit/100]) where Cv and Ca represent the concentration of t-PA in the vein and artery respectively. A positive difference indicates a net release and a negative difference net uptake. Arterial and venous blood samples are collected simultaneously at baseline and each dose of the drug (BDK) and BDK+Vit C. t-PA concentration were determined by enzyme immunoassay. Hematocrit was measured in triplicate using the standard microhematocrit technique and corrected for trapped plasma volume within the trapped red blood cells.</description>
        <time_frame>t-PA release was measured before the 12 week drug intervention and after the 12 week drug intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Metoprolol: Saline</title>
            <description>Net t-PA antigen release in response to BDK before 12 weeks of nebivolol therapy.</description>
          </group>
          <group group_id="O2">
            <title>Before Metoprolol: Vitamin C</title>
            <description>Net t-PA antigen release in response to BDK+C before 12 weeks of nebivolol therapy.</description>
          </group>
          <group group_id="O3">
            <title>After Metoprolol: Saline</title>
            <description>Net t-PA antigen release in response to BDK after 12 weeks of nebivolol therapy.</description>
          </group>
          <group group_id="O4">
            <title>After Metoprolol: Vitamin C</title>
            <description>Net t-PA antigen release in response to BDK+C after 12 weeks of nebivolol therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial t-PA Release in Response to BDK and BDK+C Before and After 12 Weeks of Metoprolol Therapy.</title>
          <description>Net endothelial release of t-PA antigen in response to BDK and BDK+C was calculated using the following equation: Net Release of t-PA Antigen=(Cv-Ca) x (FBF x [101-hematocrit/100]) where Cv and Ca represent the concentration of t-PA in the vein and artery respectively. A positive difference indicates a net release and a negative difference net uptake. Arterial and venous blood samples are collected simultaneously at baseline and each dose of the drug (BDK) and BDK+Vit C. t-PA concentration were determined by enzyme immunoassay. Hematocrit was measured in triplicate using the standard microhematocrit technique and corrected for trapped plasma volume within the trapped red blood cells.</description>
          <units>ng/100 mL tissue/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Amount of t-PA release to Saline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="0.9"/>
                    <measurement group_id="O2" value="-2.5" spread="0.8"/>
                    <measurement group_id="O3" value="-1.3" spread="1.4"/>
                    <measurement group_id="O4" value="-2.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amount of t-PA release to BDK 12.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="3.9"/>
                    <measurement group_id="O2" value="31.1" spread="5.0"/>
                    <measurement group_id="O3" value="16.4" spread="5.0"/>
                    <measurement group_id="O4" value="30.0" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amount of t-PA release to BDK 25.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="3.8"/>
                    <measurement group_id="O2" value="47.1" spread="7.3"/>
                    <measurement group_id="O3" value="31.3" spread="3.3"/>
                    <measurement group_id="O4" value="46.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amount of t-PA release to BDK 50.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="5.5"/>
                    <measurement group_id="O2" value="82.4" spread="10.2"/>
                    <measurement group_id="O3" value="49.9" spread="5.7"/>
                    <measurement group_id="O4" value="73.8" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data for each participant was assessed every 2 weeks during their check-in visits at the CU-Boulder CTRC over the 12 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nebivolol</title>
          <description>Nebivolol: 5 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Metoprolol</title>
          <description>Metoprolol: 100 mg tablet to be taken by mouth once per day for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: Gelatin capsule to be taken by mouth once per day for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christopher DeSouza</name_or_title>
      <organization>University of Colorado</organization>
      <phone>303-492-2988</phone>
      <email>desouzac@colorado.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

